Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy

Oncology

Volumn 64, Issue 4, 2003, Pages 300-305

  Petrioli, Roberto ^a   Pozzessere, Daniele ^a   Messinese, Simona ^a   Sabatino, Marianna ^a   Di Palma, Teresa ^a   Marsili, Stefania ^a   Correale, Pierpaolo ^a   Manganelli, Antonio ^a   Salvestrini, Francesco ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Docetaxel; Prostate cancer; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; EVALUATION; FATIGUE; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; PALLIATIVE CARE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS; TREATMENT OUTCOME;

EID: 0037636763     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070285     Document Type: Article

References (30)

1. Gotkas S, Crawford ED: Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999;26:162-173.
2. Prostate Cancer Trialists' Collaborative group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3,283 deaths in 5,710 patients. Lancet 1995;356:265-269.
3. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J Clin Oncol 1985;3:827-841.
4. Millikan RE: Chemotherapy of advanced prostate cancer. Semin Oncol 1999;26:185-191.
5. Slack NH, Murphy GP: Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 1984;11:337-342.
6. Dawson NA: Apples and oranges: Building a consensus for standardized eligibility criteria and endpoints in prostate cancer clinical trials. J Clin Oncol 1998;16:3398-3405.
7. Francini G, Petrioli R, Gonnelli S, Correale P, Pozzessere D, Marsili S, Montagnani A, Lucani B, Rossi B, Monaco R, Manganelli A, Salvestrini F, Fiaschi AI: Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer 2001;92:1468-1474.
8. Tannock IF, Osoba D, Stockler MR, Scott Ernst D, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomised trial with palliative endpoints. J Clin Oncol 1996;14:1756-1761.
9. Francini G, Petrioli R, Manganelli A, Cintorino M; Marsili S, Aquino A, Mondillo S: Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 1993;67:1430-1436.
10. Brausi M, Jones WG, Fossa SD, de Mulder PHM, Droz JP, Lentz M-A, van Glabeke M, Pawinski A and members of the EORTC Genitourinary Cancer Research Group: High-dose epirubicin is effective in measurable metastatic prostate cancer: A phase II study of the EORTC Genitourinary Group. Eur J Cancer 1995;31A:1622-1626.
11. Hernes EH, Fossa SD, Vaage S, Ogreid P, Heilo A, Paus E: Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study. Br J Cancer 1997;76:93-99.
12. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer. J Clin Oncol 1999;17:2506-2513.
13. Oh WK, Kantoff PW: Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol 1999;26(suppl 17):49-54.
14. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 1999;26(suppl 17):14-18.
15. Culine S, Droz JP: Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress? Ann Oncol 2000;11:1523-1530.
16. Melzack R: The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1975;1:277-299.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Fumikazu Takeda, for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. JNCI 1993;85:365-376.
18. Miller AB, Hoogstraten B, Statquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
19. Kelly Wk, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44-53.
20. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958-967.
21. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone-refractory prostate carcinoma. Ann Oncol 1999;10:33-38.
22. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509-2516.
23. Scher H, Steinneck G, Kelly WK: Hormone-refractory (D3) prostate cancer: Refining the concept. Urology 1995;46:142-148.
24. Vogelzang NJ, Crawford ED, Zietman A: Current clinical trial design issues in hormone-refractory prostate carcinoma. Consensus Panel. Cancer 1998;82:2093-2101.
25. Heidenreich A, von Knobloch R, Hofmann R: Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001;39:121-130.
26. Ganz PA: Quality of Life considerations in the older cancer patient. In Balducci L, Lyman GH, Ershel WB (eds): Comprehensive Geriatric Oncology, ed 2. Amsterdam, Harwood, 1998, pp 271-280.
27. Van Andel G, Kurth KH, Rietbroek RL, van de Velde-Muusers JA: Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxyprogesterone acetate - is it feasible? Eur Urol 2000;38:259-264.
28. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994;12:1238-1244.
29. Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26(suppl 17):19-23.
30. Petrylak DP: Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000;27(suppl 3):24-29.